Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Indalecio Monteagudo

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
Modern Rheumatology|July 2, 2014
Young male patient diagnosed with cutaneous polyarteritis nodosa successfully treated with etanerceptLara Valor, Indalecio Monteagudo, Inmaculada de la Torre, et al.
Clinical and Experimental Rheumatology|May 29, 2013
Idiopathic recurrent pericarditis treated successfully with tumour necrosis factor alpha blocking agents (anti-TNF-α)Juan Carlos Nieto González, Indalecio Monteagudo Saez, Francisco Javier López-Longo, et al.
Rheumatology International|June 20, 2018
Identifying markers of sustained remission in rheumatoid arthritis patients on long-term tapered biological disease-modifying antirheumatic drugsLara Valor, Jesús Garrido, Lina Martínez-Estupiñán, et al.
Scientific Reports|August 11, 2021
Persistence and adherence to biologic therapies in juvenile idiopathic arthritisJuan Carlos Nieto-González, Laura Trives-Folguera, Alejandra Melgarejo-Ortuño, et al.
The Journal of Rheumatology|August 1, 2023
What to Expect When Systemic Treatment in Juvenile Idiopathic Arthritis Is Withdrawn?Juan Carlos Nieto-González, Daniel Clemente Garulo, Alina Boteanu, et al.
Annals of the Rheumatic Diseases|March 3, 2007
Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trialGerd R Burmester, Xavier Mariette, Carlomaurizio Montecucco, et al.
Rheumatology International|July 1, 2018
The beliefs of rheumatoid arthritis patients in their subcutaneous biological drug: strengths and areas of concernLuis Cea-Calvo, Enrique Raya, Carlos Marras, et al.
Rheumatology International|July 27, 2018
Correction to: The beliefs of rheumatoid arthritis patients in their subcutaneous biological drug: strengths and areas of concernLuis Cea-Calvo, Enrique Raya, Carlos Marras, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 15, 2013
Anti-TNF treatments in rheumatoid arthritis: economic impact of dosage modificationInmaculada de la Torre, Lara Valor, Juan Carlos Nieto, et al.
Clinical and Experimental Rheumatology|February 10, 2015
Relation of Doppler ultrasound synovitis versus clinical synovitis with changes in native complement component levels in rheumatoid arthritis patients treated with biologic disease-modifying anti-rheumatic drugsMaria Montoro Alvarez, Ong Yew Chong, Iustina Janta, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Modern Rheumatology|July 2, 2014
Young male patient diagnosed with cutaneous polyarteritis nodosa successfully treated with etanerceptLara Valor, Indalecio Monteagudo, Inmaculada de la Torre, et al.
Clinical and Experimental Rheumatology|May 29, 2013
Idiopathic recurrent pericarditis treated successfully with tumour necrosis factor alpha blocking agents (anti-TNF-α)Juan Carlos Nieto González, Indalecio Monteagudo Saez, Francisco Javier López-Longo, et al.
Rheumatology International|June 20, 2018
Identifying markers of sustained remission in rheumatoid arthritis patients on long-term tapered biological disease-modifying antirheumatic drugsLara Valor, Jesús Garrido, Lina Martínez-Estupiñán, et al.
Scientific Reports|August 11, 2021
Persistence and adherence to biologic therapies in juvenile idiopathic arthritisJuan Carlos Nieto-González, Laura Trives-Folguera, Alejandra Melgarejo-Ortuño, et al.
The Journal of Rheumatology|August 1, 2023
What to Expect When Systemic Treatment in Juvenile Idiopathic Arthritis Is Withdrawn?Juan Carlos Nieto-González, Daniel Clemente Garulo, Alina Boteanu, et al.
Annals of the Rheumatic Diseases|March 3, 2007
Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trialGerd R Burmester, Xavier Mariette, Carlomaurizio Montecucco, et al.
Rheumatology International|July 1, 2018
The beliefs of rheumatoid arthritis patients in their subcutaneous biological drug: strengths and areas of concernLuis Cea-Calvo, Enrique Raya, Carlos Marras, et al.
Rheumatology International|July 27, 2018
Correction to: The beliefs of rheumatoid arthritis patients in their subcutaneous biological drug: strengths and areas of concernLuis Cea-Calvo, Enrique Raya, Carlos Marras, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 15, 2013
Anti-TNF treatments in rheumatoid arthritis: economic impact of dosage modificationInmaculada de la Torre, Lara Valor, Juan Carlos Nieto, et al.
Clinical and Experimental Rheumatology|February 10, 2015
Relation of Doppler ultrasound synovitis versus clinical synovitis with changes in native complement component levels in rheumatoid arthritis patients treated with biologic disease-modifying anti-rheumatic drugsMaria Montoro Alvarez, Ong Yew Chong, Iustina Janta, et al.
Pageof 5